Oxford Biomedica plc (OXB) Ordinary 50p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Oxford Biomedica shares rise on post-acquisition guidance
5 March 2024 16:22
(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market on its medium-term financial guidance.
-
Director dealings: TUI, Oxford Biomedica board members linked to buys
27 September 2023 11:24
(Sharecast News) - TUI was among those on the list of director buys on Wednesday after its chief executive officer purchased almost 50,000 shares.
-
Liberum cuts target price for Oxford Biomedica, saying it still lacks sufficient scale
28 November 2022 11:43
(Sharecast News) - Analysts at Liberum cut their target price for shares Oxford Biomedica arguing that the company's pan-vector offering had yet to reach sufficient scale in order to deliver sustainable...
-
Oxford Biomedica taps Frank Mathias as its new CEO
22 November 2022 09:30
(Sharecast News) - Gene and cell therapy specialist Oxford Biomedica announced the appointment of Dr Frank Mathias as its new chief executive officer and a board director on Tuesday, effective from March.
-
Oxford Biomedica swings to loss as Covid vaccine winds down
15 September 2022 10:27
(Sharecast News) - Oxford Biomedica reported a 21% decrease in its first-half total revenue on Thursday, to £64m.
-
Oxford Biomedica inks LSA with new US biotech partner
7 September 2022 07:42
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck a new licence and supply agreement with an unnamed US partner.
-
Oxford Biomedica inks LSA with US biotech firm, launches new project with Orchard Therapeutics
26 July 2022 08:44
(Sharecast News) - Gene and cell therapy group Oxford Biomedica inked a new licence and supply agreement with an unnamed US private biotechnology on Tuesday company and also launched a new project with...
-
Oxford Biomedica signs new Covid vaccine deal with AstraZeneca
1 July 2022 07:03
(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
-
Oxford Biomedica sees FDA lift clinical hold on Homology's HMI-102 trial
14 June 2022 09:35
(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Tuesday that the US Food and Drug Administration had notified Homology Medicines that the clinical hold on its pheNIX gene therapy...
-
Oxford Biomedica posts good growth, notes pause in vaccine making
20 April 2022 09:10
(Sharecast News) - Oxford Biomedica reported a 63% improvement in total revenues in its preliminary results on Wednesday, to £142.8m, although its outlook was somewhat less rosy amid a pause in vaccine...
-
Oxford Biomedica's Parkinson's licensee pulls out
1 February 2022 07:40
(Sharecast News) - Oxford Biomedica's licensee for a Parkinson's disease treatment has pulled out of development and returned the rights to the UK company.
-
Oxford Biomedica creates venture with Homology, launches £80m fundraise
28 January 2022 09:56
(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders,...
Company announcements Announcements
-
Total Voting Rights
2 April 2024 07:00
Oxford Biomedica
-
Update on CDMO Services
20 March 2024 07:00
Oxford Biomedica
-
Board Changes
11 March 2024 07:00
Oxford Biomedica
-
Updated Financial Guidance and 2023 Trading
5 March 2024 07:00
Oxford Biomedica
-
Total Voting Rights
1 March 2024 07:00
Oxford Biomedica
-
Appointment of Joint Corporate Broker
15 February 2024 07:00
Oxford Biomedica
-
Holding(s) in Company
1 February 2024 16:48
Oxford Biomedica
-
Total Voting Rights
1 February 2024 07:00
Oxford Biomedica
-
Block Listing Application
31 January 2024 07:00
Oxford Biomedica
-
Total Voting Rights
30 January 2024 07:00
Oxford Biomedica
-
Completion of Transaction
29 January 2024 08:38
Oxford Biomedica
-
Block listing application
26 January 2024 15:09
Oxford Biomedica
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.